FMP
Kymera Therapeutics, Inc.
KYMR
NASDAQ
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
33.35 USD
-1.86 (-5.58%)
About
ceo
Dr. Nello Mainolfi M.D., Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.kymeratx.com
exchange
NASDAQ
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fi...
CIK
0001815442
ISIN
US5015751044
CUSIP
501575104
Address
200 Arsenal Yards Boulevard
Phone
857 285 5300
Country
US
Employee
187
IPO Date
Aug 21, 2020
Summary
CIK
0001815442
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
501575104
ISIN
US5015751044
Country
US
Price
33.35
Beta
2.27
Volume Avg.
640.56k
Market Cap
2.04B
Shares
-
52-Week
9.6-45.31
DCF
-27.77
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-13.23
P/B
-
Website
https://www.kymeratx.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest KYMR News
It looks like there's no news available.
